STOCK TITAN
  1. Home
  2. Sec-filings
  3. VCEL
  4. [Form 4] Vericel Corp Insider Trading Activity

Vericel (VCEL) director McLaughlin exercises options and sells 7,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vericel Corp director Kevin F. McLaughlin reported option exercises and related stock sales in Vericel common stock. On May 13, 2026, he exercised stock options to acquire a total of 7,000 shares of common stock, including 3,500 shares at an exercise price of $13.05 per share and 3,500 shares at $2.63 per share. On the same date, he sold 7,000 shares in open‑market transactions at prices of $32.82 and $32.83 per share. After these transactions, McLaughlin directly held 18,300 shares of Vericel common stock. The filing notes that the sales were automatic transactions executed under a Rule 10b5-1 trading plan adopted on May 12, 2025.

Positive

  • None.

Negative

  • None.
Insider MCLAUGHLIN KEVIN F
Role null
Sold 7,000 shs ($230K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 3,500 $0.00 --
Exercise Stock Option (Right to Buy) 3,500 $0.00 --
Exercise Common Stock 3,500 $2.63 $9K
Sale Common Stock 3,500 $32.83 $115K
Exercise Common Stock 3,500 $13.05 $46K
Sale Common Stock 3,500 $32.82 $115K
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null); Common Stock — 21,800 shares (Direct, null)
Footnotes (1)
  1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.
Shares sold 7,000 shares Open-market sales on May 13, 2026
Sale prices $32.82 and $32.83 per share Common stock sales on May 13, 2026
Options exercised 7,000 shares Total shares from option exercises on May 13, 2026
Exercise prices $13.05 and $2.63 per share Stock option exercise prices for common stock
Shares held after 18,300 shares Direct ownership after transactions
10b5-1 plan adoption date May 12, 2025 Date trading plan governing sales was adopted
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
automatic sale financial
"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MCLAUGHLIN KEVIN F
(Last)(First)(Middle)
C/O VERICEL CORPORATION
64 SIDNEY STREET
(Street)
CAMBRIDGE MASSACHUSETTS 02139
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Vericel Corp [ VCEL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/13/2026M3,500A$2.6321,800D
Common Stock05/13/2026S3,500D(1)$32.8318,300D
Common Stock05/13/2026M3,500A$13.0521,800D
Common Stock05/13/2026S3,500D(1)$32.8218,300D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$2.6305/13/2026M3,500 (2)05/03/2027Common Stock3,500$00D
Stock Option (Right to Buy)$13.0505/13/2026M3,500 (3)05/02/2028Common Stock3,500$014,000D
Explanation of Responses:
1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025.
2. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.
3. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.
/s/ Sean Flynn, as Attorney-in-Fact for Kevin McLaughlin05/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Vericel (VCEL) director Kevin F. McLaughlin report?

Kevin F. McLaughlin reported exercising options for 7,000 Vericel shares and selling 7,000 shares. The sales were open‑market transactions executed under a pre‑arranged Rule 10b5-1 trading plan.

At what prices did Kevin F. McLaughlin sell Vericel (VCEL) shares?

He sold 7,000 Vericel common shares at approximately $32.82 and $32.83 per share. These sales occurred on May 13, 2026 as open‑market transactions under his Rule 10b5-1 trading plan.

How many Vericel (VCEL) shares does Kevin F. McLaughlin hold after these transactions?

Following the reported transactions, Kevin F. McLaughlin directly holds 18,300 shares of Vericel common stock. This figure reflects his position after exercising options and selling 7,000 shares on May 13, 2026.

What stock options did Kevin F. McLaughlin exercise in Vericel (VCEL)?

He exercised options covering 7,000 shares of Vericel common stock: 3,500 shares at a $13.05 exercise price and 3,500 shares at a $2.63 exercise price, both originally granted in 2017 and 2018.

Were Kevin F. McLaughlin’s Vericel (VCEL) stock sales pre-planned?

Yes. The filing states the sales were automatic transactions under a Rule 10b5-1 trading plan adopted on May 12, 2025, indicating they were pre‑scheduled rather than discretionary market‑timing decisions.